**Vertex Pharmaceuticals’ Journavx (suzetrigine) Wins US FDA Approval More Than 20 Years for Adult Pain Treatment**

On Thursday, the US Food and Drug Administration approved the first new type of pain reliever in over 20 years.

Journavx (suzetrigine), a prescribed medication of 50 milligrams, is taken twice daily with an initial dose. This drug, also known as suzetrigine, will soon be available in the market.

According to Dr. Jacqueline Corrigan-Curay, the FDA is dedicated to approving safe and effective alternatives to opioids for pain management. She explains that a new non-opioid analgesic therapeutic class has been developed for acute pain, which not only offers patients another treatment option but also helps mitigate risks associated with using opioids. The FDA’s expedited review process further emphasizes their commitment to providing alternative therapies for pain relief.

According to government surveys, analgesics are the most frequently prescribed drugs in hospitals.

According to research conducted by Vertex Pharmaceuticals, approximately 80 million individuals in the United States receive prescriptions annually for addressing moderate to severe pain. Of all these prescriptions, roughly 50% are for opioid medications, which may result in dependency and addiction due to their nature.

Journavx, the latest pain-relieving medication authorized in the US, is also classified as a Cox-2 inhibitor like Celebrex – the last drug of its kind approved almost two decades ago in 1998.

According to Dr. Sergio Bergese, an anesthesiologist at Stony Brook University’s Renaissance School of Medicine, various body parts are instrumental in experiencing pain. Nerve cells transmit an electrical impulse from the damaged tissue to the brain, where it is interpreted as pain.

In contrast to opioid drugs, which numb the brain’s ability to feel pain, Journavx functions by inhibiting the firing of pain-signaling nerves throughout the body.

According to Bergese, this medication disrupts the pathway, preventing the brain from being aware of tissue injury, even though it still exists.

Importantly, Journavx does not induce any feelings of euphoria or a “high” similar to opioids, leading doctors to believe it has no potential for causing addiction or dependence in its users.

After learning about a family of fire walkers in Pakistan, researchers discovered that they lacked a gene responsible for feeling pain in their skin. As a result, these individuals were able to confidently walk over hot coals without showing any signs of discomfort.

They were aware that they were onto something significant; they could sense the heat of the coals. It does not affect the nerves responsible for warmth and sensitivity. According to Stuart Arbuckle, chief operating officer of Vertex Pharmaceuticals, “In all other aspects, they were typical.”

Scientists took a quarter of a century to utilize this pain-transmitting process for the creation of medication.

According to Dr. Stephen Waxman, the Center for Neuroscience and Regeneration Research at the Yale School of Medicine found that neurons communicate through nerve impulses, which can be likened to Morse code.

Nerve impulses are created by small molecular batteries found in neuron membranes, also known as sodium channels.

Suzetrigine achieves its function by blocking a specific sodium channel responsible for transmitting pain signals.

Multiple attempts have been made to discover a drug capable of inhibiting a single type of sodium channel. According to Waxman, the approval of Suzetrigine suggests that there may be other drugs with even greater efficacy waiting in the wings.

According to Waxman, who has no financial connections to the new medication, this is a significant advancement as it demonstrates the effectiveness of a [sodium-channel blocker] in alleviating pain in humans.

This presents the opportunity for a second wave of highly potent [medications].

Suzetrigine comes in two different dosages. During the study, participants were initially prescribed 100 milligrams, and then continued to take 50 milligrams every 12 hours.

Medical professionals emphasize that the medication may not be suitable for all individuals or all forms of pain.

Two clinical trials, with a combined total of nearly 600 participants, displayed suzetrigine’s superiority in managing pain following both abdominal and foot surgeries, compared to an inactive placebo pill.

An equal number of individuals experienced a decrease in pain by half after surgery with suzetrigine and Vicodin, a blend of acetaminophen and hydrocodone.

Although the research did not intend to directly compare suzetrigine to Vicodin, it is difficult to determine which one was more effective.

According to a commonly used 0-10 rating system, the participants in the study began with an average pain level of seven. With the use of suzetrigine, this was lowered by approximately 3.5 points.

According to Arbuckle, this is not equivalent to completely getting rid of pain. It would instead result in a 50% decrease in pain.

In another trial involving individuals suffering from sciatica-induced back pain, suzetrigine showed a decrease of approximately 2 points in pain levels, which was also observed in participants who received a placebo. This implies that the effectiveness of this medication for chronic pain may not be remarkable.

According to Vertex, their drug has been successfully tested on various forms of chronic pain and has shown promising results in treating long-term pain. As part of their ongoing research, they are also conducting trials on individuals with diabetic neuropathy – a condition caused by prolonged exposure to high blood sugar levels that can result in symptoms such as numbness, tingling, pain, and muscle weakness.

Due to its smaller size, the sciatica study comprised of approximately 100 individuals in both the suzetrigine and placebo groups. This limited number of participants may have hindered the ability to observe significant distinctions between the two groups. It should also be noted that placebos often yield considerable impacts in pain studies, further complicating their analysis.